β-Confident-registry: aiming to be largest-ever studied cohort of cryopyrin-associated periodic syndromes (CAPS) patients. Study design and baseline characteristics

Míreanna Comhchosúla

• Long-term safety and efficacy of Canakinumab in cryopyrin-associated periodic syndrome (CAPS) patients: results from beta-confident registry
  le: Kuemmerle-Deschner, J, et al.
  Foilsithe: (2015)
• Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the β-Confident Registry
  le: Walker, Ulrich A, et al.
  Foilsithe: (2021)
• Methodological challenges in monitoring new treatments for rare diseases: lessons from the cryopyrin-associated periodic syndrome registry
  le: Tilson, Hugh, et al.
  Foilsithe: (2013)
• Diagnosis and Management of the Cryopyrin-Associated Periodic Syndromes (CAPS): What Do We Know Today?
  le: Welzel, Tatjana, et al.
  Foilsithe: (2021)
• National CAPS (Cryopyrin-Associated Periodic Syndrome) Registry
  le: Bibalo, C, et al.
  Foilsithe: (2011)